|
US20030022311A1
(en)
|
1996-05-21 |
2003-01-30 |
Dunnington Damien D. |
Human CIS protein
|
|
US6323317B1
(en)
|
1996-11-01 |
2001-11-27 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic and diagnostics proteins comprising a SOCS box
|
|
AU7267398A
(en)
|
1997-04-30 |
1998-11-24 |
Hans Klingemann |
Natural killer cell lines and methods of use
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
CA2480052A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
JP2008522951A
(ja)
|
2004-07-19 |
2008-07-03 |
ベイラー・カレツジ・オブ・メデイシン |
サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
|
|
US7863240B2
(en)
|
2004-10-08 |
2011-01-04 |
Enzo Therapeutics, Inc. |
Methods and uses of leptin in hepatocellular carcinoma
|
|
US7868159B2
(en)
|
2005-06-23 |
2011-01-11 |
Baylor College Of Medicine |
Modulation of negative immune regulators and applications for immunotherapy
|
|
EP1940460A4
(en)
*
|
2005-10-27 |
2009-08-12 |
Biogen Idec Inc |
OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
|
|
WO2008060331A2
(en)
*
|
2006-05-19 |
2008-05-22 |
Amgen Inc. |
Antibodies to sars coronavirus
|
|
DK2356270T3
(da)
|
2008-11-07 |
2016-12-12 |
Fabrus Llc |
Kombinatoriske antistofbiblioteker og anvendelser deraf
|
|
US20120192298A1
(en)
|
2009-07-24 |
2012-07-26 |
Sigma Aldrich Co. Llc |
Method for genome editing
|
|
WO2012078540A1
(en)
|
2010-12-08 |
2012-06-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
CA2932547C
(en)
*
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
ES3063961T3
(en)
*
|
2014-02-14 |
2026-04-21 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
MX373460B
(es)
|
2014-03-11 |
2020-04-07 |
Cellectis |
Metodo para generar celulas t compatibles para el trasplante alogenico.
|
|
AU2015259877B2
(en)
*
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
WO2015187521A2
(en)
*
|
2014-06-03 |
2015-12-10 |
Merck Sharp & Dohme Corp. |
Anti-blys antibodies
|
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
CA2976089C
(en)
|
2015-02-10 |
2026-01-13 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
US10100118B2
(en)
*
|
2015-04-08 |
2018-10-16 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD123
|
|
CA2997444A1
(en)
*
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors for reducing cholesterol levels
|
|
KR102438360B1
(ko)
|
2016-03-04 |
2022-08-31 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
|
|
EP3519443A4
(en)
|
2016-09-30 |
2020-06-10 |
Baylor College of Medicine |
CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
|
|
CA3041831A1
(en)
|
2016-10-27 |
2018-05-03 |
Intima Bioscience, Inc. |
Viral methods of making genetically modified cells
|
|
US20230192896A1
(en)
*
|
2016-11-23 |
2023-06-22 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
US20180100016A1
(en)
|
2016-12-22 |
2018-04-12 |
Xiaotong Song |
Use of car-modified human natural killer cells to treat cancer
|
|
CN118271442A
(zh)
*
|
2016-12-23 |
2024-07-02 |
蓝鳍生物医药公司 |
抗sez6l2抗体和抗体药物缀合物
|
|
JP2020503043A
(ja)
|
2016-12-30 |
2020-01-30 |
セルラリティ インコーポレイテッド |
遺伝子改変されたナチュラルキラー細胞
|
|
KR102660336B1
(ko)
|
2017-03-27 |
2024-04-26 |
내셔널 유니버시티 오브 싱가포르 |
절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
US11497768B2
(en)
*
|
2017-06-05 |
2022-11-15 |
Mie University |
Antigen-binding protein that recognizes MAGE-A4-derived peptide
|
|
SG11201912010XA
(en)
*
|
2017-06-12 |
2020-01-30 |
Obsidian Therapeutics Inc |
Pde5 compositions and methods for immunotherapy
|
|
WO2019006418A2
(en)
*
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CN111788301A
(zh)
*
|
2017-11-24 |
2020-10-16 |
昂克治疗有限公司 |
靶向肿瘤细胞的经修饰的自然杀伤细胞和自然杀伤细胞系
|
|
KR102780406B1
(ko)
*
|
2018-02-01 |
2025-03-17 |
화이자 인코포레이티드 |
Cd70을 표적으로 하는 키메라 항원 수용체
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
CN110351878B
(zh)
*
|
2018-04-04 |
2023-07-14 |
华为技术有限公司 |
一种随机接入处理方法和相关设备
|
|
US12227763B2
(en)
|
2018-05-11 |
2025-02-18 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
JP2021530223A
(ja)
*
|
2018-07-09 |
2021-11-11 |
スロゼン， インコーポレイテッド |
組織特異性Ｗｎｔシグナル増強分子及びその使用
|
|
US20210338727A1
(en)
*
|
2018-09-13 |
2021-11-04 |
Nkarta, Inc. |
Natural killer cell compositions and immunotherapy methods for treating tumors
|
|
JP7629414B2
(ja)
|
2019-06-04 |
2025-02-13 |
ンカルタ・インコーポレイテッド |
免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
|
|
CA3144871A1
(en)
|
2019-06-27 |
2020-12-30 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
US12344656B2
(en)
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
IL292467A
(en)
|
2019-11-13 |
2022-06-01 |
Crispr Therapeutics Ag |
Treatment of hematopoietic cell cancers using genetically engineered t cells targeting cd70
|
|
BR112022009137A2
(pt)
|
2019-11-13 |
2022-07-26 |
Crispr Therapeutics Ag |
Métodos de fabricação de células t com receptor de antígeno quimérico (car)
|
|
BR112022009204A2
(pt)
|
2019-11-13 |
2022-07-26 |
Crispr Therapeutics Ag |
Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70
|
|
KR20220119038A
(ko)
|
2019-11-25 |
2022-08-26 |
케이에스큐 세러퓨틱스 인코포레이티드 |
종양 침윤 림프구의 활성화 및 확장을 위한 방법
|
|
CN115297890A
(zh)
|
2020-02-03 |
2022-11-04 |
国立大学法人东海国立大学机构 |
用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
|
|
WO2021231773A1
(en)
*
|
2020-05-13 |
2021-11-18 |
Good Therapeutics, Inc. |
Compositions of protein complexes and methods of use thereof
|
|
WO2021252804A1
(en)
|
2020-06-12 |
2021-12-16 |
Nkarta, Inc. |
Genetically modified natural killer cells for cd70-directed cancer immunotherapy
|
|
JP2023536818A
(ja)
|
2020-07-29 |
2023-08-30 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
|
|
CN116322716A
(zh)
|
2020-09-23 |
2023-06-23 |
克里斯珀医疗股份公司 |
Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
|
|
JP2023552998A
(ja)
*
|
2020-12-03 |
2023-12-20 |
ンカルタ・インコーポレイテッド |
効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
|
|
AR125852A1
(es)
|
2021-05-12 |
2023-08-16 |
Crispr Therapeutics Ag |
Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
|
|
WO2022238962A1
(en)
|
2021-05-12 |
2022-11-17 |
Crispr Therapeutics Ag |
Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
|
|
CA3254363A1
(en)
|
2022-03-07 |
2023-09-14 |
Nkarta, Inc. |
Multiplex gene-edited cells for CD70-led cancer immunotherapy
|